Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases

Journal of Dermatological Treatment

Volumn 20, Issue 2, 2009, Pages 100-108

  Ko, Justin M ^a   Gottlieb, Alice B ^a   Kerbleski, Joseph F ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Blockade; Exacerbation; Psoriasis; Therapy; TNF

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYTOKINE; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; CELL TYPE; CROHN DISEASE; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; INFORMATION RETRIEVAL; JUVENILE RHEUMATOID ARTHRITIS; MEDLINE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; ADOLESCENT; ADULT; AGE; AGED; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; FEMALE; HOSPITALIZATION; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROGNOSIS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67650216399     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630802441234     Document Type: Review

References (90)

1. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223-43.
2. Walsh SJ, Rau LM. Autoimmune diseases: A leading cause of death among young and middle-aged women in the United States. Am J Public health. 2000;90:1463-6.
3. As found on product websites:http://www.enbrel.com/? channel=GOSEA&= SENC,http://www.remicade.com/ remicade/global/index.html, and http://www.humira.com/. Accessed 15 August 2007.
4. Efthimiou P, Markenson JA. Role of biological agents in immune-mediated infammatory diseases. South Med J. 2005;98:192-204.
5. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A for the Etanercept Psoriasis Study Group, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
6. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Effcacy and safety of infiximab monotherapy for plaque type psoriasis: A randomised trial. Lancet. 2001;357:1842-7.
7. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829-30.
8. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor. N Engl J Med. 2002;346:1349-56.
9. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-25.
10. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, Mccloskey R, et al. Reduction of chemokine levels and leukocyte traffc to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:38-47.
11. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-94.
12. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infiximab: A randomised controlled multicentre trial. Lancet. 2002;359:1187-93.
13. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-56.
14. Braughman RPI, Lower EE. Infiximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;118:70-4.
15. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl M. Improvement of pyoderma gangrenosum and psoriasis associated with crohn's disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930-3.
16. Richlin C. Newer therapeutic approaches: Spondyloarthritis and uveitis. Rheum Dis Clin North Am. 2006;32:75-90.
17. Sfkakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infiximab for recurrent, sight-threatening ocular infammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140:404-6.
18. Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: Use of targeted immunotherapeutics as pathogenic probes. Lupus. 2003;12:190-4.
19. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley L, Baker D. Infiximab monotherapy provides rapid and sustained beneft for plaque-type psoriasis. J Am Acad Dermatol. 2003;48:829-35.
20. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-32.
21. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Res Ther. 2005;7:r666-76.
22. Baeten D, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infiximab: A new perspective on the role of host defense in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829-34.
23. Roux CH, Brocq O, Leccia N, Giacchero D, Breuil V, Albert c, et al. New-onset psoriatic palmoplantaris pustulosis following infiximab therapy: A class effect? J Rheumatol. 2007;34:434-7.
24. Lee HH, Song Ih, Friedrich M, Gauliard A, Detert J, Röwert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486-91.
25. Sfkakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis rheum. 2005;52:2513-18.
26. Aslanidis S, Pyrpasopoulou A, Leontsini M, Zamboulis c. Anti-TNF-alpha-induced psoriasis: Case report of an unusual adverse event. Int J Dermatol. 2006;45:982-3.
27. Matthews C, Rogers S, Fitzgerald O. Development of new-onset psoriasis while on anti-TNFα treatment. Ann Rheum Dis. 2006;65:1529-30.
28. Cohen JD, Bournerias I, Buffard V, Paufer A, Chevalier X, Bagot M, et al. Psoriasis induced by tumor necrosis factor alpha antagonist therapy: A case series. J Rheumatol. 2007;34:380-5.
29. Seneschal J, Heliot-hosten I, Bouysou-gauthier ML, et al. Eruption psoriasiforme sous anti-TNF alpha: Un mecanisme toxidermique? [abstract]. Rev Rhum. 2005;72:1009.
30. Kary S, Worm M, Fritz J, et al. New onset of aggravating of psoriatic skin lesions in patients with defnitive rheumatoid arthritis under treatment with TNF-alpha antagonists: Report of 8 cases [abstract]. Ann Rheum Dis. 2004;63:(suppl):276.
31. Haibel H, Spiller I, Strasser C. Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with tNF-alpha blocking agents [abstract]. Ann Rheum Dis. 2004;63:(suppl):405.
32. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: Two cases. Br J Dermatol. 2004;151:506-7.
33. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infiximab treatment: Comment on the article by Beuthien, et al. Arthritis Rheum. 2005;52:1333-4.
34. Starmans-kool MJ, Peeters HR, Houben HH. Pustular skin lesions in patients treated with infiximab: Report of two cases. Rheumatol Int. 2005;25:550-2.
35. Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of fexural psoriasis during infiximab treatment for Crohn's disease. Clin Exp Dermatol. 2005;30:713-14.
36. Adams Dr, Buckel T, Sceppa JA. Infiximab-associated newonset psoriasis. J Drugs Dermatol. 2006;5:178-9.
37. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infiximab. Ann Pharmacother. 2004;38:54-7.
38. Peek R, Scott-jupp R, Strike H, Clinch J, Ramanan AV. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis. 2006;65:1259.
39. Cassano N, Coviello C, Loconsole F, Miracapillo A, Vena GA. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy. Eur J Dermatol. 2006;16:316-17.
40. Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: Three further cases and current overview. Dermatology. 2006;213:182-6.
41. Goiriz R, Daudén E, Pérez-gala S, Guhl G, García-díez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol. 2007;32:176-9.
42. Ubriani R, Van Voorhees AS Onset of psoriasis during treatment with TNF-α antagonists: A report of 3 cases. Arch Dermatol. 2007;143:270-2.
43. Takahashi H, Hashimoto Y, Ishida-Yamamoto I, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infiximab. J Dermatol. 2007;34:468-72.
44. Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol. 2006;33:1411-14.
45. Papadavid E, Gazi S, Dalamaga M, Stavrianeas N, Ntelis V. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: A case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol. 2008;22:380-2.
46. Martínez-morán C, Sanz-muñoz C, Morales-callaghan AM, Torrero V, Miranda-romero A. Pustular psoriasis induced by infiximab. J Eur Acad Dermatol. 2007;21:1424-6.
47. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004;50:1690-2.
48. Djennane S, Oro S, Lévy-weil FE, Sigal M, Feldman JL. Psoriasis cutané induit par traitement anti-TNF alpha au cours d'une fasciite éosinophile [abstract]. Rev Rhum. 2005;72:10-1.
49. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford). 2006;45:730-3.
50. Goncalves DP, Laurindo I, Scheinberg MA. The appearance of pustular psoriasis during antitumor necrosis factor therapy. J Clin Rheumatol. 2006;12:262.
51. Richette P, Viguier M, Bachelez H, Bardin T. Psoriasis induced by anti-tumor necrosis factor therapy: A class effect? J Rheumatol. 2007;34:438.
52. Zarnitsky C, Bravard P, Godon J, Alcaix D. Pustulose palmaire et plantaire chez une patiente traitée par adalimumab. Rev Rhum. 2005;72:1195.
53. Umeno J, Matsumoto T, Jo Y, Ichikawa M, Urabe K, Iida M. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Infamm Bowel Dis. 2007;13:1188-9.
54. Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli C. Another paradox in Crohn's disease: New onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Infamm Bowel Dis. 2007;13:1059-61.
55. Heymann WR. Tumor necrosis factor inhibitor-induced pustular psoriasis? J Am Acad Dermatol. 2007;56:327-9.
56. deGannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatic conditions. Arch Dermatol. 2007;143:223-31.
57. Thurber M, Feasel A, Stroehlein J, Hymes Sr. Pustular psoriasis induced by infiximab. J Drugs Dermatol. 2004;3:439-40.
58. Michaelsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol. 2006;54:737-8.
59. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sörensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoi d arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405-7.
60. Cavailhes A, Ingen-housz-oro S, Djennane S, Rafaa M, Fiszenson-albala F, Weber N, et al. Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infiximab. Ann Dermatol Venereol. 2007;134:(4 Pt 1)363-7.
61. Chustecka Z. Psoriasis with TNF inhibitors: Is there an infectious etiology? Accessed July 29, 2007. URL: http://www.jointandbone.org/viewArticle. do?primaryKey=569511
62. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infiximab and etanercept? Clin Infect Dis. 2005;41:S199-203.
63. Lowes MA, Chamian F, Abello MV, Leonardi C, Dummer W, Papp K, et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: A case series. BMC Dermatol. 2007;7:2.
64. Hassan AS, Simon D, Simon HU, Braathen Lr, Yawalkar N. Efalizumab-associated papular psoriasis. Arch Dermatol. 2007;143:900-6.
65. Herron M, Kinckley M, Hoffman M, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527-34.
66. Ammoury A, El Sayed F, Dhaybi R, Bazex J. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol. 2008;22:392-3.
67. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: A clinical and immunohistological study. Br J Dermatol. 1998;138:390-8.
68. Hagforsen E, Nordlind K, Michaelsson G. Skin nerve fbres and their contacts with mast cells in patients with palmoplantar pustulosis. Arch Dermatol Res. 2000;292:269-74.
69. Niizeki H, Naruse T, Hashigucci K, Yokoyama M, Yamasaki Y, Akiya K, et al. Polymorphism in the TNFA promoter region gene is not associated with palmoplantar pustulosis. Tissue Antigens. 2000;56:162-5.
70. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997;109:562-5.
71. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infiximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol. 2005;153:1243-4.
72. Van der Fits L, Van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon alpha sensitivity is unaltered. J Invest Dermatol. 2004;122:51-60.
73. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol. 2005;125:936-44.
74. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003;200:255-68.
75. Nestle FO, Gilliet M. Defning upstream elements of psoriasis pathogenesis: An emerging role for interferon alpha. J Invest Dermatol. 2005;125:xiv-xv.
76. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFNalpha in autoimmune disease. Proc Natl Acad Sci U S A. 2005;102:3372-7.
77. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005;44:172-5.
78. Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, et al. CD8+ T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity. 2000;13:643-55.
79. Nestle FO, Conrad C, Tun-kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202:135-43.
80. Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist Imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140:1490-5.
81. Ladoyanni E, Nambi R. Psoriasis exacerbated by interferonalpha in a patient with chronic myeloid leukemia. J Drugs Dermatol. 2005;4:221-2.
82. Saissi EH, Beau-Salinas F, Jonville-Béra AP, Lorette G, Autret-Leca E, et al. Centres Régionaux de Pharmacovigilance. [Drugs associated with acute generalized exanthematic pustulosis.] Ann Dermatol Venereol. 2003;130:612-18.
83. Spencer JM, Silvers DN, Grossman ME. Pustular eruption after drug exposure: Is it pustular psoriasis or a pustular drug eruption? Br J Dermatol. 1994;130:514-19.
84. Carter JD. Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists. Ann Rheum Dis. 2006;65:1680.
85. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infiximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:15941-602.
86. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infiximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002;359:1541-9.
87. Sakai T, Kawaguchi M, Ishizawa S, Kaji T, Kitagawa K, Koizumi F. Histological features of palatine tonsils in pustulosis palmaris and plantaris: A morphometric study. Pathol Int. 1994;44:186-93.
88. Teranishi Y, Mizutani h, Murata M, Shimizu M, Matsushima K. Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: Relation to focal infection and response to treatments. J Dermatol Sci. 1995;10:8-15.
89. Sfikakis PP, Kollias G. Tumor necrosis factor in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15:380-6.
90. Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med. 1991;174:1461-6.